Core Insights - The article highlights the top and bottom AH premium rates for various stocks, indicating significant disparities in market valuations between A-shares and H-shares [1][2] - Northeast Electric (00042) leads with a premium rate of 900.00%, while CATL (03750) shows a negative premium rate of -4.93%, suggesting potential investment opportunities and risks [1] AH Premium Rate Rankings - The top three stocks with the highest AH premium rates are: - Northeast Electric (00042) with a premium of 900.00% and a deviation value of 34.85% [1] - Hongye Futures (03678) with a premium of 272.56% and a deviation value of 8.87% [1] - Zhejiang Shibao (01057) with a premium of 261.81% and a deviation value of 5.38% [1] - The bottom three stocks with the lowest AH premium rates are: - CATL (03750) with a premium of -4.93% and a deviation value of 6.10% [1] - China Merchants Bank (03968) with a premium of -1.58% and a deviation value of -1.24% [1] - Heng Rui Medicine (01276) with a premium of 0.64% and a deviation value of -2.66% [1] Deviation Value Rankings - The top three stocks with the highest deviation values are: - Guanghetong (00638) with a deviation value of 36.62% [1] - Northeast Electric (00042) with a deviation value of 34.85% [1] - Beijing Machinery (00187) with a deviation value of 27.48% [1] - The bottom three stocks with the lowest deviation values are: - GAC Group (02238) with a deviation value of -20.57% [1] - Jiangsu Ninghu Highway (00177) with a deviation value of -13.89% [1] - Shenzhen Expressway (00548) with a deviation value of -12.04% [1]

Core Viewpoint - FTSE Russell announced adjustments to several indices, including the FTSE China 50 Index, FTSE China A50 Index, FTSE China A150 Index, FTSE China A200 Index, and FTSE China A400 Index, effective after the market close on December 19, 2025 [1][17]. Group 1: Index Adjustments - The FTSE China A50 Index will include Luoyang Molybdenum and Sungrow Power, while removing Jiangsu Bank and SF Holding [3][19]. - The FTSE China 50 Index will add China Hongqiao, CATL, and Heng Rui Medicine, and remove CITIC Securities, Great Wall Motors, and Li Auto [5][21]. - The FTSE China A150 Index will add Ying Shi Innovation, Jiangsu Bank, Huadian New Energy, SF Holding, Jiangbolong, and Huayou Cobalt, while removing Luoyang Molybdenum, Desay SV, Longi Green Energy, Baoxin Software, Shanghai Pharmaceuticals, and Sungrow Power [9][25]. - The FTSE China A200 Index will include Ying Shi Innovation, Huadian New Energy, Jiangbolong, and Huayou Cobalt, and exclude Desay SV, Longi Green Energy, Baoxin Software, and Shanghai Pharmaceuticals [11][27]. - The FTSE China A400 Index will see a broader adjustment, adding Anji Technology, Baiyin Nonferrous Metals, Yitang Co., and BlueFocus, while removing Chipbond Technology, Yipin Hong, Guanghuan Xin, and Huaxi Biological [12][28]. Group 2: Investment Implications - The adjustments by FTSE Russell are expected to attract passive fund allocations to the included stocks and increase overseas interest in Chinese assets [15][31]. - In the first ten months of 2025, foreign capital inflow into the Chinese stock market reached $50.6 billion, significantly surpassing the $11.4 billion for the entire year of 2024, marking an increase of over three times [15][31]. - UBS forecasts that the A-share market will see an increase in earnings growth from 6% this year to 8% next year, driven by improved nominal GDP growth and a narrowing of PPI declines [16][32]. - Morgan Stanley has set a target for the CSI 300 Index at 4,840 points by December 2026, indicating a stable outlook for Chinese stocks amid moderate earnings growth and higher valuation levels [16][32].

Core Viewpoint - Heng Rui Medicine (01276) announced the appointment of Zhu Guoxin as the Senior Vice President, effective from the date of the board meeting approval until the current board's term ends [1] Group 1 - The board of directors approved the proposal for the appointment of a Senior Vice President [1] - The appointment is based on the company's operational development needs [1]

Core Viewpoint - FTSE Russell announced adjustments to several indices including the FTSE China 50 Index, which will take effect after market close on December 19, 2025 [1] Group 1: Index Adjustments - The FTSE China 50 Index will include new constituents such as China Hongqiao (01378), CATL (03750), and Heng Rui Pharmaceutical (01276) [1] - The index will exclude companies like CITIC Securities H (06066), Great Wall Motors H (02333), and Li Auto-W (02015) [1] Group 2: Alternative Stocks - FTSE Russell released a list of alternative stocks for the FTSE China 50 Index, which includes companies like Aluminum Corporation of China (02600), Hansoh Pharmaceutical (03692), Huatai Securities (06886), JD Health (06618), and New China Life Insurance (01336) [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 孫飄揚先生 中國上海 2025年12月3日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-193 江苏恒瑞医药股份有限公司 第九届董事会第二十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的 ...

Core Viewpoint - FTSE Russell announced adjustments to several indices, including the FTSE China 50 Index, which will take effect after the market closes on December 19, 2025, with changes in constituent stocks [1] Group 1: Index Adjustments - The FTSE China 50 Index will include new constituents such as China Hongqiao (01378), CATL (03750), and Heng Rui Pharmaceutical (01276) [1] - The index will remove companies like CITIC Securities H shares (06066), Great Wall Motors H shares (02333), and Li Auto-W (02015) [1] Group 2: Alternative Stocks - FTSE Russell released a list of alternative stocks for the FTSE China 50 Index, which includes companies like Aluminum Corporation of China (02600), Hansoh Pharmaceutical (03692), Huatai Securities (06886), JD Health (06618), and New China Life Insurance (01336) [1]

Core Insights - The article highlights the top and bottom AH share premium rates as of December 3, with Northeast Electric (00042) leading at a premium rate of 900.00% [1][2]. Group 1: Top AH Share Premium Rates - Northeast Electric (00042) has the highest premium rate at 900.00% with H-share priced at 0.270 HKD and A-share at 2.25 CNY [2]. - Hongye Futures (03678) follows with a premium rate of 276.85%, H-share at 3.240 HKD and A-share at 10.19 CNY [2]. - Sinopec Oilfield Service (01033) ranks third with a premium rate of 265.79%, H-share at 0.760 HKD and A-share at 2.32 CNY [2]. Group 2: Bottom AH Share Premium Rates - Contemporary Amperex Technology (03750) has the lowest premium rate at -4.88%, with H-share priced at 473.600 HKD and A-share at 376.08 CNY [2]. - China Merchants Bank (03968) has a premium rate of -0.25%, H-share at 51.650 HKD and A-share at 43.01 CNY [2]. - Heng Rui Medicine (01276) follows with a premium rate of 1.71%, H-share at 71.800 HKD and A-share at 60.97 CNY [2]. Group 3: Premium Deviation Values - Guanghe Communication (00638) has the highest deviation value at 49.00% [1][3]. - Northeast Electric (00042) also features prominently with a deviation value of 36.60% [1][3]. - Chenming Paper (01812) ranks third with a deviation value of 26.74% [1][3]. Group 4: Bottom Premium Deviation Values - GAC Group (02238) has the lowest deviation value at -26.76% [1][3]. - Junsheng Electronics (00699) follows with a deviation value of -18.54% [1][3]. - Jiangsu Ninghu Highway (00177) has a deviation value of -15.01% [1][3].

Core Points - Jiangsu Hengrui Medicine Co., Ltd. has received the acceptance notice from the National Medical Products Administration for its drug application of injectable remimazolam tosylate [2] Group 1 - Drug Name: Injectable Remimazolam Tosylate [2] - Dosage Form: Injectable [2] - Acceptance Number: CXHS2500146 [2] - Application Stage: Market Approval [2] - Applicant: Jiangsu Hengrui Medicine Co., Ltd. [2] - Proposed Indication: Sedation during mechanical ventilation in intensive care [2]

Core Viewpoint - Heng Rui Medicine (01276) has announced the progress of its A-share repurchase plan, indicating a strategic move to enhance shareholder value through share buybacks [1] Group 1: Share Repurchase Details - In November 2025, the company repurchased 979,900 shares through the Shanghai Stock Exchange, accounting for 0.015% of the total share capital, with a maximum purchase price of RMB 63.28 per share and a minimum of RMB 59.32 per share, totaling RMB 59.7885 million (excluding transaction fees) [1] - As of November 30, 2025, the cumulative repurchase amounted to 8,898,700 shares, representing 0.13% of the total share capital, with a maximum price of RMB 70.00 per share and a minimum of RMB 59.32 per share, totaling RMB 595 million (excluding transaction fees) [1]

Core Viewpoint - Heng Rui Medicine (01276) has received the acceptance notice from the National Medical Products Administration for the marketing authorization application of injectable toremifene, indicating progress in its product pipeline [1] Group 1: Product Development - The injectable toremifene has been approved for indications including sedation and anesthesia during non-tracheal intubation surgeries and for induction and maintenance of general anesthesia [1] - The application for market approval is based on two key studies focused on sedation for mechanically ventilated patients in the Intensive Care Unit (ICU) [1] Group 2: Clinical Research - The HR7056-302 study is a Phase III clinical trial evaluating toremifene compared to standard first-line treatments for short-term sedation during critical care, involving 214 patients across 43 centers, led by Professor Guan Xiangdong from Sun Yat-sen University First Affiliated Hospital [1] - The HR7056-206 study is a multi-center Phase II clinical trial assessing toremifene for long-term sedation in critical care, with 24 patients enrolled from 18 centers, led by Professor Shen Feng from Guizhou Medical University Affiliated Hospital [1] - Both studies achieved their primary endpoints as expected [1]